Read More

Anemia Advantage For GSK’s Blood Cancer Therapy Could Influence Market Share Despite Incyte’s Jakafi Comparison

Friday, the FDA approved GSK plc's (NYSE: GSK) Ojjaara (momelotinib) for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and post-essential thrombocythaemia), in 

BMY